Conclusions: This study demonstrates a paradigm shift in the treatment of primary mycotic abdominal aortic aneurysms (MAAAs) in Sweden to the use of endovascular aneurysm repair (EVAR) as the preferred modality. EVAR was associated with improved short-term survival in comparison to open repair and without a higher incidence of serious infectious complications or reoperations.
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Summary: This retrospective study of a prospectively collected nationwide database spanned 10 years . All patients treated for a primary MAAAs were identified in the Swedish vascular registry (Swedvasc) . The primary aim was assessment of survival after open repair (OR) or EVAR of a MAAA. Secondary end points were analysis of the rate of recurrent infections and reoperations as well as the time trends in surgical treatment. Propensity score-weighted correction for risk factors in the 2 groups was performed including the operative year to account for differences in treatment and outcome over time. One hundred and thirty-two patients were identified (0.6% of all AAA repairs) with mean age of 70. Rupture was the presenting symptom in 50 patients. Overall survival was 86% at 3 months, 79% at 1 year, and 59% at 5 years. The treatment modality shifted over this study, EVAR was not used prior to 2001 (n ¼ 14 repairs), jumped to 58% during 2001-2007 (n ¼ 43 repairs) , and was used 60% of the time during 2008-2014 (n ¼ 75 repairs). Eight patients had multiple aortic aneurysms defined as a combination of infrarenal, paravisceral, and/or thoracic. The most common infectious agents were Streptococcus (22%), Staphlococcus (16%), and Salmonella (9%). Of the 62 patients treated with open repair, 50 were in situ reconstructions, 7 aortic resections and extra-anatomic bypasses, and 3 patch angioplasties. Two patients died intraoperatively. There were 70 EVAR repairs (55 standard, 8 fenestrated/ branched, and 7 visceral deviation and stent graft and without an interventional death). Antibiotics were administered for a median of 12 weeks (OR, and EVAR, 16 weeks ). Eight had percutaneous drainage (2 OR, 6 EVAR). Survival at 3 months was lower for OR than EVAR (74% vs 96%; P < .001), with a like trend at 1 year (73% vs 84%; P ¼ .54). Ruptured MAAAs had a higher mortality (74%) than intact MAAA repairs (93%; P ¼ .003). Twenty-eight patients experienced an infectionrelated complication (21%) of which 46% were fatal but no association could be found between the presence of positive blood cultures, bacterial species present, or duration of antibiotic use. The median time until infection-related complication was 3 months and 75% occurred within the first year after surgery. The propensity score-weighted risk-adjusted analysis confirmed better early survival with EVAR. At five years comparing OR to EVAR, there was no difference in long-term survival (60% vs 58%; P ¼ .77), infection-related complications (18% vs 24%; P ¼ .44) and reoperation (21% vs 24%; P ¼ .65).
Comments: It should be clarified that the patients presented in this study are primary aortic infections presenting as aneurysmal disease and signs/symptoms/finding of infection. It is the currently largest such series in the literature. Excluded are primary aortoenteric fistula, inflammatory aneurysms, graft infections, graft-enteric fistulas and those with prior aortic surgery. The data do not allow a determination of preinterventional antibiotics use or duration. It does not have the detail to provide patient factors which might favor the recommendation of one approach over the other. However, it does provide data to suggest that EVAR can be a durable treatment of primary aortic infection; a viable option in the elderly, those in shock or immunosuppressed who otherwise might not be consider candidates for intervention; and, in a few (four cases in this series) a bridge to open surgery.
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Conclusions: Dual antiplatelet therapy demonstrates advantages over single therapy only in patients treated with a carotid artery stent as determined by a decrease risk of transient ischemia attack. Dual therapy was associated with an increased risk of major bleeding, neck hematoma and MI in those undergoing carotid endarterectomy with no benefit regarding protection from transient ischemic attack (TIA)/stroke/ mortality.
Summary: Electronic information sources and bibliographic reference lists were searched to identify randomized controlled trials and observational studies reporting comparative outcomes of dual versus single antiplatelet therapy in CEA and CAS. Both asymptomatic and symptomatic patients were included of any age and gender but excluding those within 14 days of thrombolysis given for the management of acute stroke. Primary outcomes were 30 day mortality and stroke. Secondary outcomes were TIA, major bleeding, groin or neck hematoma and MI. Initial search found 1172 articles; 1128 were not relevant, comparative or were systemic reviews; 18 were duplicates; 5 were added from references but another 12 excluded for lack of primary outcome, had no carotid intervention or were not comparing dual verses single antiplatelet agent. The remaining were three randomized controlled trials (RCTs) and seven observational studies. One RCT and seven retrospective observational studies reporting a total of 36,881 CEAs, of which 8536 were in the dual therapy and 27,320 in the single-agent treatment group and 1101 received no antiplatelet therapy. Aspirin and clopidogrel were the antiplatelet treatment in all studies. Demographic and clinical characteristics were not statistically different between single and dual treatment groups. Symptomatic patient outcomes were available in 6 studies and 3 studies provide dual antiplatelet therapy mainly for symptomatic patients. Only two studies reported the type of postoperative stroke of which only one was hemorrhagic. There was no difference in stroke (0.91% vs 0.79%), TIA (1.30% vs 1.12%) or 30-day mortality (0.21% vs 0.25%) between single and dual therapy. There was a significant increased risk of major bleeding (0.83% vs 1.27%: RD, 0.00; 95% confidence interval [CI], 0.00-0.01; P ¼ .0003), neck hematoma (6.77% vs 8.19%: RD, 0.04; 95% CI, 0.01-0.06; P ¼ .001) and rate of MI (1.11% vs 0.73%: RD, 0.00; 95% CI, 0.00-0.01; P ¼ .003). when using dual therapy. The Grade of evidence was estimated as low for all analyses. Statistical heterogeneity was general low or not present. Two RCTs evaluated dual versus single therapy in 150 CAS procedures, 75 in each group. Acetylsalicylic acid, clopidogrel, and ticlopidine were the agents used and in both trials patients in the single therapy group were provided heparin infusion for 24 hours postintervention as well. There was no demographic or clinical characteristics difference between groups and both provided data on symptomatic patients. One study provided information on the type of stroke postintervention and no hemorrhagic strokes were reported. In CAS single versus dual therapy, the was no statistical difference in mortality (0% vs 1.3%), stroke (4% vs 0%), MI (0% in each), major bleeding (0% in each) or groin hematoma (8% vs 4%) but a significant difference was identified in the risk of TIA in favor of dual therapy (14.6% vs 1.3%: RD, À0.13; 95% CI, À0.22 to À0.05; P ¼ .003). The grade of evidence was estimated as moderate for all analyses with no statistical heterogeneity. The dual agent in 2/3 rd of the patients was ticlopidine in addition to acetylsalicylic acid.
Comments: This study does support the use of dual therapy post-CAS to decrease the risk of TIA. The small number of patients in the analyses introduces a potential statistical bias and the majority of patients were treated with a drug (ticlopidine) removed from the market. For CEA, dual therapy provides no neurologic protection but does add bleeding and potentially a worse MI outcome. The study does not provide information on platelet function which can be an issue with clopidogrel nonresponders. It is apparent from the authors' discussion of study limitations and grade of evidence that the final word regarding dual therapy use postcarotid intervention is yet to be determined.
